Chemomab Therapeutics Ltd. financial data

Symbol
CMMB on Nasdaq
Location
Tel Aviv
Fiscal year end
31 December
Latest financial report
6-K - Q2 2025 - 14 Aug 2025

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 377,132,220 shares 33%
Common Stock, Shares, Outstanding 413,851,140 shares 44%
Common Stock, Value, Issued $0 USD
Weighted Average Number of Shares Outstanding, Basic 286,080,133 shares 29%
Weighted Average Number of Shares Outstanding, Diluted 286,080,133 shares 29%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $2,928,000 USD -42%
General and Administrative Expense $840,000 USD -74%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $3,631,000 USD 54%
Income Tax Expense (Benefit) $0 USD -100%
Net Income (Loss) Attributable to Parent $2,057,000 USD 43%
Earnings Per Share, Basic 0.01 USD/shares -56%
Earnings Per Share, Diluted 0.01 USD/shares -56%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $5,448,000 USD 8.2%
Cash, Cash Equivalents, and Short-term Investments $9,500,000 USD
Assets, Current $10,614,000 USD -21%
Property, Plant and Equipment, Net $217,000 USD -21%
Operating Lease, Right-of-Use Asset $0 USD -100%
Assets $11,129,000 USD -23%
Employee-related Liabilities, Current $386,000 USD -29%
Accrued Liabilities, Current $666,000 USD -74%
Liabilities, Current $1,430,000 USD -67%
Operating Lease, Liability, Noncurrent $0 USD -100%
Liabilities $1,430,000 USD -69%
Retained Earnings (Accumulated Deficit) $108,003,000 USD -12%
Stockholders' Equity Attributable to Parent $9,699,000 USD -2.9%
Liabilities and Equity $11,129,000 USD -23%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 4,650,000,000 shares 0%
Common Stock, Shares, Issued 413,851,140 shares 44%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $5,596,000 USD 9.5%
Deferred Tax Assets, Valuation Allowance $44,219,000 USD 1.7%
Deferred Tax Assets, Gross $44,219,000 USD 1.7%
Operating Lease, Liability $324,000 USD -17%
Lessee, Operating Lease, Liability, to be Paid $346,000 USD -25%
Property, Plant and Equipment, Gross $529,000 USD 0%
Operating Lease, Liability, Current $0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two $120,000 USD 4.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $22,000 USD -69%
Lessee, Operating Lease, Liability, to be Paid, Year Three $120,000 USD -0.83%
Deferred Tax Assets, Operating Loss Carryforwards $40,755,000 USD 6.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four $106,000 USD -12%
Additional Paid in Capital $117,702,000 USD 11%
Deferred Tax Assets, Net of Valuation Allowance $0 USD